Abbott Laboratories (ABT)
132.60
-4.76 (-3.47%)
At close: Mar 11, 2025, 3:59 PM
133.16
0.43%
After-hours: Mar 11, 2025, 08:00 PM EDT
-3.47% (1D)
Bid | 132.08 |
Market Cap | 229.97B |
Revenue (ttm) | 42.01B |
Net Income (ttm) | 13.42B |
EPS (ttm) | 7.64 |
PE Ratio (ttm) | 17.36 |
Forward PE | 22.46 |
Analyst | Buy |
Ask | 134.25 |
Volume | 6,615,370 |
Avg. Volume (20D) | 6,348,634 |
Open | 136.50 |
Previous Close | 137.36 |
Day's Range | 132.31 - 137.06 |
52-Week Range | 99.71 - 141.23 |
Beta | 0.69 |
About ABT
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepa...
Industry Medical - Devices
Sector Healthcare
IPO Date Mar 17, 1980
Employees 114,000
Stock Exchange NYSE
Ticker Symbol ABT
Website https://www.abbott.com
Analyst Forecast
According to 16 analyst ratings, the average rating for ABT stock is "Buy." The 12-month stock price forecast is $135, which is an increase of 1.81% from the latest price.
Stock ForecastsNext Earnings Release
Abbott Laboratories is scheduled to release its earnings on Apr 16, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+4.62%
Abbott shares are trading higher after multiple an...
Unlock content with
Pro Subscription
4 months ago
+4.61%
Abbott Laboratories shares are trading higher after the company announced it along with Reckitt Benckiser won its first trial in premature-infant formula litigation and is cleared of allegations of hiding bowel disease risks.